FDA approves Emcitate as first treatment for MCT8 deficiency

The FDA has approved Emcitate as the first treatment for MCT8 deficiency, providing a therapy for the peripheral thyrotoxicosis associated with this ultra-rare genetic disorder.

Emcitate (tiratricol) is approved for adults and paediatric patients with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome.

The first-in-disease approval provides a treatment designed to act without relying on the defective MCT8 transporter responsible for the disorder.

Field	Content
Article Type	Approvals
Drug Name	Tiratricol
Brand Name	Emcitate
Regulatory Authority	U.S. Food and Drug Administration
Approval Type	First FDA-approved treatment for MCT8 deficiency
Indication	Peripheral thyrotoxicosis in adults and paediatric patients with MCT8 deficiency
Therapy Areas	Rare disease; endocrinology; neurology
Disease	MCT8 deficiency / Allan-Herndon-Dudley syndrome
Technology/Modality	Thyroid hormone analogue
Geography	United States
What Happened	The FDA approved Emcitate for peripheral thyrotoxicosis in adults and paediatric patients with MCT8 deficiency.
Why It Matters	Emcitate is the first FDA-approved treatment for MCT8 deficiency, addressing an ultra-rare genetic disorder with no previously approved therapy.
Supporting Context	MCT8 deficiency results from defects in the MCT8 thyroid hormone transporter and is also known as Allan-Herndon-Dudley syndrome.
Potential Impact	The approval establishes the first US pharmacological treatment option for patients with MCT8 deficiency.
Key Takeaway	Emcitate becomes the first FDA-approved treatment for MCT8 deficiency.
What to Watch	US launch, patient access and longer-term evidence from treatment in adults and children.
Primary Source	U.S. Food and Drug Administration
Relevant Date	28 September 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com